Delayed hCG Trigger Does Not Improve Oocyte Maturation Rate: Evidence From 9,319 IVF/ICSI Cycles Using Three Controlled Ovarian Hyperstimulation Protocols

Why It Matters

Clinics can avoid unnecessary delays in hCG administration, potentially improving IVF success and reducing cycle costs.

Key Takeaways

• Delaying hCG trigger does not raise oocyte maturation rates.
• Only depot GnRHa ICSI cycles showed reduced maturation with high DFP.
• ICSI linked to higher low‑maturation risk versus conventional IVF.
• Greater oocyte yield and GnRHa protocols lower low‑maturation risk.
• Individualized, protocol‑specific trigger timing recommended over follicle size alone.

Pulse Analysis

In assisted reproductive technology, the decision of when to administer the human chorionic gonadotropin (hCG) trigger is a pivotal step that influences oocyte quality and ultimately pregnancy rates. Clinicians often monitor follicle size, aiming for a higher proportion of dominant follicles (DFP) under the assumption that larger, more mature follicles will yield better‑aged oocytes. However, the balance between maximizing follicular development and preserving oocyte competence remains uncertain, especially across the three most common controlled ovarian hyperstimulation (COH) protocols—depot GnRHa, long GnRHa, and GnRH antagonist.

The recent analysis of 9,319 first‑time IVF/ICSI cycles from a single Chinese center provides robust evidence that postponing the hCG trigger to increase DFP does not improve maturation outcomes. Across all three COH regimens, overall DFP showed no statistical link to maturation rate, and only depot GnRHa cycles using ICSI experienced a modest decline when DFP exceeded 60 %. Moreover, the data reveal that ICSI itself raises the odds of a low‑maturation (<40 %) result, while higher oocyte yield, older patient age, and GnRHa protocols mitigate that risk.

These findings encourage fertility programs to shift from a one‑size‑fits‑all trigger strategy toward a more nuanced, protocol‑specific approach. By avoiding unnecessary delays, clinics can preserve oocyte integrity, shorten stimulation periods, and potentially lower medication costs for patients. The study also underscores the need for further prospective trials to refine trigger timing algorithms, incorporate patient‑specific factors such as ovarian reserve, and evaluate downstream effects on embryo quality and live‑birth rates. Tailoring hCG administration promises to enhance efficiency and outcomes in modern IVF practice.